MET and non-small cell lung carcinoma: This study is the first economic evaluation of MET inhibitors in Chinese NSCLC patients with METex14 skipping and, therefore, offers a valuable contribution to the emerging understanding of health and cost outcomes associated with gumarontinib and savolitinib in this patient population.